THE IMPACT OF COMORBIDITIES IN STABLE ANGINA PECTORIS CLASS I PATIENTS ON MEDICATION COSTS: A CASE STUDY

Authors

  • Roma Ave Maria Santo Borromeus University, Indonesia https://orcid.org/0000-0002-9578-5132
  • Adi Anggoro Santo Borromeus University, Indonesia
  • Salwa Azzah Imtiyaz Padjadjaran University, Indonesia
  • Muchlis Halim Santo Borromeus University, Indonesia

DOI:

https://doi.org/10.24269/ijhs.v10i1.12189

Abstract

Stable angina pectoris class I is a cardiovascular condition requiring long-term therapy, significantly contributing to medication costs for patients and the National Health Insurance (JKN). This study, titled “The Impact of Comorbidities in Stable Angina Pectoris Class I Patients on Medication Costs: A Case Study at Hasan Sadikin Hospital, Bandung, December 2023,” aims to analyze drug cost distribution based on therapeutic regimens (preventive, first-line, and second-line treatments) among patients with and without comorbidities such as hypertension, diabetes mellitus, and hypercholesterolemia. Using a quantitative cross-sectional design with retrospective data from medical records, 300 outpatients diagnosed with stable angina pectoris class I were selected through purposive sampling according to specific criteria. Data collected included demographics, comorbidity profiles, therapeutic regimens, and drug costs. Multiple linear regression was applied to determine the effect of comorbidities on medication expenses. The findings are expected to describe medication cost distribution across therapeutic lines and reveal the impact of comorbidities on outpatient treatment costs. Results may serve as input for BPJS Kesehatan and hospitals in evaluating cost efficiency and highlight the importance of preventing comorbid conditions to reduce treatment expenses.

Downloads

Download data is not yet available.

References

[1] AHA, “What is angina?” American Heart Association, 2020. [Online]. Available: https://www.heart.org
[2] A. A. Adnan, “The Correlation Between Modifiable Risk Factors and Coronary Heart Disease Incidence in Patients at RSUP Dr. Wahidin Sudirohusodo Pusat Jantung Terpadu Makassar City for January–June 2021 Period,” Ph.D. dissertation, Univ. Hasanuddin, 2022.
[3] B. Eka, I. Sari, M. Arfania, A. Jasmine, A. Ayu, and K. Syifa, “Terapi antikoagulan pada penderita angina pektoris,” J. Pendidik. dan Konseling, vol. 5, pp. 5520–5535, 2023.
[4] Ch. Bachmid and Zulkifli, “Analisis heart rate recovery pasca uji jalan 6 menit terhadap major adverse cardiovascular events jangka pendek pada pasien ST-elevation myocardial infarction dengan diabetes mellitus di RSUP Dr. Wahidin Sudirohusodo,” Ph.D. dissertation, Univ. Hasanuddin, 2024.
[5] M. Böhm, R. Ferrari, I. Ford, et al., “The role of drug therapy in the management of stable angina,” Eur. Heart J., 2019. [Online]. Available: https://academic.oup.com
[6] S. F. Candradewi, D. A. Perwitasari, and N. Nabilah, “Analisis biaya dan luaran klinis sindrom koroner akut berbasis clinical pathway,” J. Manaj. dan Pelayanan Farm., vol. 11, no. 2, pp. 91–97, 2021, doi: 10.22146/jmpf.51176.
[7] L. Clement, “Terapi antiangina untuk angina pektoris stabil,” Cermin Dunia Kedokteran, vol. 49, no. 12, pp. 702–707, 2022, doi: 10.55175/cdk.v49i12.330.
[8] Direktorat Jenderal Pelayanan Kesehatan, “Iskemia miokardial,” Jan. 17, 2025. [Online]. Available: https://yankes.kemkes.go.id/view_artikel/2540/iskemia-miokardial
[9] A. Dyer, J. Wallace, and T. Chen, “Cost analysis of angina pectoris,” Health Econ. Rev., 2018. [Online]. Available: https://www.springer.com
[10] S. D. Fihn, J. C. Blankenship, K. P. Alexander, et al., “2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the management of patients with stable ischemic heart disease,” Circulation, 2014. [Online]. Available: https://circ.ahajournals.org
[11] H. Hildebrandt, E. Jørgensen, and T. Schmidt, “Invasive vs. conservative treatment in patients with stable angina pectoris,” Heart, 2016.
[12] Kemenkes RS Hasan Sadikin, “Mengenal JKN | Rumah Sakit Dokter Hasan Sadikin Bandung,” accessed Nov. 24, 2024. [Online]. Available: https://web.rshs.go.id/mengenal-jkn/
[13] Kementerian Kesehatan Republik Indonesia, Laporan Tahunan Jaminan Kesehatan Nasional (JKN), 2021. [Online]. Available: https://www.kemkes.go.id
[14] Kementerian Kesehatan Republik Indonesia, Riset Kesehatan Dasar (Riskesdas) 2018. Jakarta: Kemenkes RI, 2018.
[15] J. Knuuti, W. Wijns, A. Saraste, et al., “ESC guidelines for the diagnosis and management of chronic coronary syndromes,” Eur. Heart J., vol. 41, no. 4, pp. 407–477, 2020, doi: 10.1093/eurheartj/ehz425.
[16] M. Mulhayana, N. Y. K. Gea, and R. S. Simamora, “The correlation of hypertension with the risk of incident coronary artery disease in elementary school teachers in Dukuhkarya Village in 2022,” J. Medicare, vol. 1, no. 4, pp. 143–154, 2022, doi: 10.62354/jurnalmedicare.v1i4.14.
[17] C. E. Niluh, S. H. Rampengan, and E. L. Jim, “Gambaran penyakit jantung koroner pada pasien gagal jantung yang menjalani rawat inap di RSUP Prof. Dr. R. D. Kandou Manado periode September–November 2016,” e-CliniC, vol. 4, no. 2, 2016, doi: 10.35790/ecl.4.2.2016.14557.
[18] F. J. Neumann et al., “2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes,” Eur. Heart J., vol. 41, no. 3, pp. 407–477, 2020, doi: 10.1093/eurheartj/ehz425.
[19] D. I. W. Nugroho, L. P. Sukmawati, and T. F. Y. Utami, “Analisis biaya pengobatan pasien penyakit jantung koroner dengan penyakit penyerta di rumah sakit,” J. Ilm. JOPHUS J. Pharm. UMUS, vol. 2, no. 2, pp. 29–40, 2021, doi: 10.46772/jophus.v2i02.428.
[20] R. Pangestu, D. Kusuma, and L. Wahyuni, “Economic evaluation of healthcare interventions in Indonesia: Current status and future directions,” Global Health Action, 2020. [Online]. Available: https://www.tandfonline.com
[21] A. M. Susanti, Hubungan Kadar Interleukin 6 (IL 6) dengan Kadar Small Dense Low Density Lipoprotein (sd LDL) pada Pasien Penyakit Jantung Koroner (PJK). Jakarta: Penerbit NEM, 2023.
[22] I. Rahmawati, D. Dwiana, and R. S. Ratiyun, “Hubungan diabetes melitus dengan penyakit jantung koroner pada pasien yang berobat di poli jantung,” J. Kesehatan Dr. Soebandi, vol. 8, no. 1, pp. 56–62, 2020, doi: 10.36858/jkds.v8i1.169.
[23] S. Safitri, A. Mappahya, Nurhikmawati, Wisudawan, and A. Safitri, “Hubungan faktor risiko kejadian hiperkolesterolemia pasien rawat jalan jantung koroner RS Ibnu Sina Makassar,” J. Mahasiswa Kedokteran, vol. 2, no. 5, pp. 359–367, 2022.
[24] S. Santoso, Statistik Deskriptif dan Inferensial. Jakarta: Salemba Empat, 2019.
[25] Sugiyono, Metode Penelitian Kuantitatif, Kualitatif, dan R&D. Bandung: Alfabeta, 2018.
[26] A. E. D. P. Syukri, “Profil penyakit jantung koroner di IRINA F Jantung RSUP Prof. Dr. R. D. Kandou Manado,” e-CliniC, vol. 1, no. 1, pp. 1–8, 2013, doi: 10.35790/ecl.1.1.2013.6036.
[27] Tommy, “Angina Prinzmetal – Diagnosis dan tatalaksana,” Cermin Dunia Kedokteran, vol. 48, no. 6, p. 315, 2021, doi: 10.55175/cdk.v48i6.1431.
[28] T. Turap, T. B. Merupakan, T. B. Lebih, and T. D. Turap, PERKI – Angina Pektoris Stabil, pp. 1–17, 2025.
[29] D. Xiang, Y. Liu, S. Zhou, E. Zhou, and Y. Wang, “Protective effects of estrogen on cardiovascular disease mediated by oxidative stress,” Oxid. Med. Cell. Longev., 2021, Art. no. 5523516, doi: 10.1155/2021/5523516.

Downloads

Published

2026-03-25

Issue

Vol. 10 No. 1 (2026): March

Section

Artikel

Citation Check

License

Copyright (c) 2026 Indonesian Journal for Health Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with Indonesian Journal for Health Sciences (IJHS) agree to the following terms:

1. Copyright and License
The copyright of articles published in the Indonesian Journal for Health Sciences is transferred to and held by the journal/publisher. Authors agree to transfer the copyright of their accepted articles to the Indonesian Journal for Health Sciences. All published articles are distributed under a Creative Commons Attribution-ShareAlike (CC BY-SA) license. This license allows others to share, adapt, and build upon the work in any medium or format, including for commercial purposes, provided that appropriate credit is given to the original source and that any derivative works are distributed under the same license..

2. Author Rights
Authors are permitted and encouraged to share their work online (e.g., in institutional repositories, personal websites, or academic networking platforms) before and during the submission process, as this can lead to productive academic exchanges and increased citation of the published work. Authors may archive the pre-print, post-print, or publisher’s PDF version of their article with an acknowledgment of its initial publication in Indonesian Journal for Health Sciences.

3. Copyright Transfer Agreement
Indonesian Journal for Health Sciences requires authors to complete and sign a formal Copyright Transfer Agreement (CTA) form before publication. The form confirms that the submitted work is original, has not been published elsewhere, and that all authors agree to transfer the publication rights to the journal for the purpose of dissemination and indexing.
The form can be downloaded here

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.